Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
作者： Ulrike D. Sent , Marcus Stark , Ingo Lang
DOI:
关键词:
摘要: The present invention relates to a method of prophylaxis or treatment systemic diseases in cats, wherein the comprising administration therapeutically effective amount angiotensin II receptor 1 (AT-1) antagonist (sartan) cat need such treatment.
lens.org参考文章(87)
M Brownfield, R A Henik, J Armstrong, J Jensen, Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease. American Journal of Veterinary Research. ,vol. 58, pp. 535- 540 ,(1997)
Cecilia Gutierrez, Catherine S Snively, Chronic kidney disease: prevention and treatment of common complications. American Family Physician. ,vol. 70, pp. 1921- 1928 ,(2004)
Michael H. Court, David J. Greenblatt, Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. Biochemical Pharmacology. ,vol. 53, pp. 1041- 1047 ,(1997) , 10.1016/S0006-2952(97)00072-5
Andrew L. Allen, The diagnosis of acetaminophen toxicosis in a cat. Canadian Veterinary Journal-revue Veterinaire Canadienne. ,vol. 44, pp. 509- 510 ,(2003)
Isaac Julius Asiedu-Gyekye, Daniel A. Antwi, Does losartan prevent cerebral edema? A preliminary study using a vascular compartment model. Medical Science Monitor. ,vol. 9, ,(2003)
隆一 加藤, M. N. Cayen, Ronald W. Estabrook, Xenobiotic metabolism and disposition : proceedings of the 2nd International ISSX Meeting, Kobe, Japan, May 16-20, 1988 Taylor & Francis. ,(1989)
Marc De Gasparo, Randy Lee Webb, Method of treatment and pharmaceutical composition ,(1999)
Masayuki Matsukura, Hiroki Ishihara, Kazutoshi Miyake, Naoki Yoneda, Nobuyuki Mori, Norio Minami, Toshiyuki Matsuoka, Osamu Hiroshima, Sachiyuki Hamano, Takashi Musha, Biphenylmethane derivative, the use of it and pharmacological compositions containing same ,(1990)
Brian Guth, Randolph Seidler, Juergen Daemmgen, Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations ,(2001)